Načítá se...
Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
BACKGROUND: Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in general, its efficacy in patients who did...
Uloženo v:
| Vydáno v: | BMC Neurol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8063415/ https://ncbi.nlm.nih.gov/pubmed/33892641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02196-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|